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The ANRS PRIMO is a prospective multicenter French
Cohort which had enrolled 1433 patients during primary-
HIV-1 infection (PHI) since 1996, with the objectives to
improve pathophysiological knowledge on PHI, to assess
the impact of an early antiretroviral treatment and to con-
tribute to document the epidemiology of new infections in
France. Clinical and laboratory data are collected at inclu-
sion, month (M)1, M3, M6, and then every 6 months. All
patients are antiretroviral-naïve at inclusion.
Patients were included early after infection (median
time, 31 days; 26% acute infection); 84% were men. The %
of patients infected with non-B subtypes increased in the
last decade, while the frequency of resistant viral strains
remained stable. At inclusion, median CD4 cell counts
and viral HIV load were 518/mm
3 and 5.1 log10 copies/mL
at PHI, with a wide range of values in the whole popula-
tion (IQR, 372-678/mm
3 and 4.5-5.7 log respectively),
depending only partially to the time from infection. Med-
ian cellular DNA at inclusion was 3.4 log cp/10
6 PBMCs
(IQR, 2.9-3.7). Early immunological (CD4 counts) and vir-
ological parameters (HIV RNA and DNA) could predict
the risk of progression to a CD4 count < 350 cells/mm
3 in
untreated patients and the chance of spontaneous persis-
tent control of viral replication after infection. 52% of
patients initiated an antiretroviral treatment at inclusion.
Although a transient treatment during PHI did not trans-
late into a benefit in terms of viral set-point compared to
untreated patients, it could lead to long term preservation
of CD4 cell counts. Furthermore, we showed that rare
treated patients were capable of controlling viral replica-
tion after treatment interruption, those patients had lower
viral reservoir at inclusion before treatment and at treat-
ment interruption compared to non controllers. Cellular
activation was high during PHI and declined substantially
thereafter, with lower levels in patients treated early after
infection compared to patients treated during the chronic
phase.
Antiretroviral treatment is now given in less advanced
infection and even discussed as a universal approach to
prevent HIV transmission. The question of treatment
initiation in all patients diagnosed during PHI is relevant.
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